Megalencephalic leukoencephalopathy with subcortical cysts (MLC), a rare leukodystrophy characterized by macrocephaly, subcortical fluid cysts and myelin vacuolation, has been linked to mutations in the MLC1 gene. This gene encodes a membrane protein that is highly expressed in astrocytes. Based on MLC pathological features, it was proposed that astrocyte-mediated defects in ion and fluid homeostasis could account for the alterations observed in MLC-affected brains. However, the role of MLC1 and the effects of pathological mutations on astrocyte osmoregulatory functions have still to be demonstrated. Using human astrocytoma cells stably overexpressing wild-type MLC1 or three known MLC-associated pathological mutations, we investigated MLC1 involvement in astrocyte reaction to osmotic changes using biochemical, dynamic video imaging and immunofluorescence techniques. We have found that MLC1 overexpressed in astrocytoma cells is mainly localized in the plasma membrane, is part of the Na,K-ATPase-associated molecular complex that includes the potassium channel Kir4.1, syntrophin and aquaporin-4 and functionally interacts with the calcium permeable channel TRPV4 (transient receptor potential vanilloid-4 cation channel) which mediates swelling-induced cytosolic calcium increase and volume recovery in response to hyposmosis. Pathological MLC mutations cause changes in MLC1 expression and intracellular localization as well as in the astrocyte response to osmotic changes by altering MLC1 molecular interactions with the Na,K-ATPase molecular complex and abolishing the increase in calcium influx induced by hyposmosis and treatment with the TRPV4 agonist 4aPDD. These data demonstrate, for the first time, that MLC1 plays a role in astrocyte osmo-homeostasis and that defects in intracellular calcium dynamics may contribute to MLC pathogenesis. †
INTRODUCTION
Megalencephalic leukoencephalopathy with subcortical cysts (MLC, OMIM 604004) is a rare autosomal recessive white matter disease in children characterized by macrocephaly at birth, subcortical cysts and swollen appearance of the white matter evidenced by magnetic resonance imaging (1) . Motor functions degenerate along with cerebellar ataxia and spasticity, while cognitive functions appear less affected and patients show a variable degree of mild cognitive impairment (1, 2) . The disease is also characterized by a slowly progressive clinical course that can be worsened by minor stress, particularly minor head trauma and common infections (3 -5) . Epileptic seizures are frequently observed in MLC. Histopathological analysis of MLC brain biopsies revealed myelin splitting and intramyelinic vacuolation, structural alterations of the blood-brain barrier, along with astroglia activation and presence of enlarged vacuoles in the end-feet of vesselcontacting astrocytes (1, 6, 7) .
A broad spectrum of pathogenic mutations has been identified in the MLC1 gene without any clear correlation with MLC disease severity (8, 9) . Some mutations are quite frequent in certain populations indicating a founder effect (10, 11) . Recently, mutations in a second gene have been found in a percentage of MLC-affected patients that do not carry mutations in MLC1, indicating the possible polygenic origin of this disease (12) . The human MLC1 gene product is a 377-amino acid protein (MLC1) (8, 13, 14) that is highly expressed in brain astrocytes, Bergmann glia and ependymal cells lining the ventricles (13, 15, 16) . In the human brain, MLC1 is predominantly localized in the plasma membrane of perivascular and subpial astrocytic processes and in astrocyte-astrocyte junctions (7, 13, 15) . MLC1 shows no similarities with proteins of known function, except for a very low homology with a subunit of the voltage-gated potassium (K) channel (Kv1.1) and an ABC type of transporter (2, 17) . Altogether, the pathological alterations observed in MLC patients (in particular, swollen white matter, fluid cysts and myelin and astrocyte vacuolation) and the localization of MLC1 in astrocyte end-feet-contacting brain barriers led to hypothesize a role for MLC1 in astrocyte-mediated processes regulating fluid and ion exchanges in the central nervous system. In support of this hypothesis, we recently demonstrated that MLC1 directly binds the beta1 subunit of the Na,K-ATPase enzyme and is part of a multiprotein complex involved in the regulation of ion transport and cellular volume in brain astrocytes during hyposmotic stress (18) .
Astrocytes are multifunctional cells that play an essential role in myelin formation, neuronal activity and maintenance of neural tissue homeostasis through the regulation of ions, neurotransmitters and metabolites in the extracellular space (19, 20) . By expressing water and ion channels at their end-foot processes at the interface between the brain and liquid spaces, astrocytes are the first cells to be exposed and react to environmental changes (21, 22) . Astrocyte alterations are associated with an increasing number of disease conditions (23 -27) , including leukodystrophies (21, (28) (29) (30) .
To elucidate the role of MLC1 in astrocyte physiology and the possible functional consequences of MLC1 mutations, we have generated and characterized human astrocytoma cell lines overexpressing wild-type (WT) MLC1 and three missense mutations described in MLC patients. Here, we show that distinct pathological mutations differently alter MLC1 intracellular localization and interaction with the Na,K-ATPase-associated multiprotein complex in astrocytoma cells and affect the response to osmotic changes. Moreover, we demonstrate that MLC1 functionally interacts with the transient receptor potential vanilloid-4 cation channel (TRPV4) to increase intracellular calcium influx in response to hyposmosis and to the TRPV4 agonist 4-alpha-phorbol 12,13-didecanoate (4aPDD). Conversely, mutations hampering MLC1 expression in the plasma membrane fail to activate calcium influx both after hyposmotic shock and 4aPDD treatment. These data show for the first time that MLC1-induced defects in the intracellular calcium response in astrocytes may contribute to the pathogenesis of MLC disease.
RESULTS

Generation and characterization of astrocytoma cell lines overexpressing WT and mutated MLC1
To study the functional changes induced by MLC1 mutations in astrocytes, we have generated human astrocytoma (U251MG) cell lines that overexpress three single-missense mutations (S246R, S280L, C125R) associated with MLC (9 and references therein) (Fig. 1A) . These mutations were previously characterized for their effect on MLC1 protein localization and stability after expression in heterologous cell systems and rat astrocytes. S246R was characterized as a mild mutant, while S280L and C125R were characterized as more severe mutants (14) . Because U251 cells express MLC1 mRNA but very low levels of the MLC1 protein (16) and originate from astrocytes, we reasoned that they could represent a better experimental model to study the functional consequences of WT and mutated MLC1 expression in the appropriate cellular context. MLC1 mutations were generated by site-directed mutagenesis (31) and the cDNAs were subcloned with a His-tag at the NH 2 moiety in a retroviral vector system to originate stably infected cell lines, as described in Materials and Methods. Expression of recombinant proteins was evaluated with western blot (WB). By loading 40 mg of protein extracts derived from the infected cell lines, we observed a high level of expression of recombinant MLC1 proteins, while endogenous MLC1 was undetectable in the parental cell line infected with the mock vector (Fig. 1B) . The expression level of MLC1 S246R was higher than that of MLC1 S280L and MLC1 C125R (Fig. 1B) most probably due to different degradation kinetics of MLC1-mutated proteins (14) .
Possible changes in MLC1 intracellular localization due to pathological mutations were investigated with double immunofluorescence techniques. Using an anti-MLC1 Ab and FITC-conjugated phallacidin which stains actin filaments, we observed that in both WT and S246R cells, MLC1 immunoreactivity localized in cytoplasmic organelles and membranes, particularly in the plasma membrane, astrocyte extensions and at the level of astrocyte -astrocyte contacts, showing a distribution similar to that of actin filaments (Fig. 1C) . Conversely, S280L and C125R mutant proteins Boor (9) ]. MLC1 mutations overexpressed in astrocytoma cell lines are indicated in colours. (B) WB analysis of protein extracts (40 mg) of astrocytoma cells infected with empty vector (CTR), or with vectors expressing WT and MLC1 mutations S246R, S280L and C125R. Expression levels of MLC1 WT and MLC1 S246R are higher than those of MLC1 S280L and MLC1 C125R. MLC1 endogenous protein is undetectable in control cells. Actin is used as internal loading control. Molecular weight markers are indicated on the left (kDa). (C) Immunofluorescence stainings of U251 astrocytoma cell lines overexpressing WT and mutated MLC1 with anti-MLC1 pAb (red) and FITC-conjugated phallacidin (green) to stain actin filaments show a similar distribution of MLC1 in the perinuclear region and along astrocytic plasma membranes in MLC1 WT and S246R mutant-expressing cells. MLC1 and actin colocalize in astrocytic extensions and astrocyte intercellular contacts (arrows). A different distribution of MLC1 (red) is observed in S280L and C125R mutant-expressing cells where MLC1-mutated proteins fail to reach the plasma membrane and are retained in the cytoplasmic perinuclear area. Scale bars ¼ 10 mm.
failed to reach the plasma membrane and were mostly retained in the cytoplasmic perinuclear areas (Fig. 1C) . By combining anti-MLC1 Ab with an Ab specific for the endoplasmic reticulum (ER) marker calnexin, we observed that similarly to WT MLC1, the S246R mutant was only in part localized in the ER while both S280L and C125R MLC1 proteins were almost exclusively confined to this compartment (Fig. 2) .
Effect of pathological mutations on MLC1 interaction with the Na,K-ATPase pump
We recently showed that in rat, primary astrocyte MLC1 interacts with the Na,K-ATPase pump and, through this, binding is part of a multiprotein complex that includes the inwardly rectifying potassium channel 4.1 (Kir4.1), syntrophin and caveolin-1, all proteins involved in the response of astrocytes to hyposmotic stress (18) . We therefore investigated the interaction of MLC1 with the Na,K-ATPase protein complex and the pathophysiological relevance of this interaction in astrocytoma cells overexpressing WT and mutated MLC1. Double immunofluorescence stainings with Abs specific for MLC1 and the Na,K-ATPase b1 subunit (NaK-b1) showed that in WT and S246R, astrocytoma cells MLC1 colocalized with NaK-b1 in the plasma membrane, where NaK-b1 is normally abundantly expressed, perinuclear region and intracellular organelles (Fig. 3) , as observed in rat astrocytes (18) . Conversely, in S280L-and C125R-expressing astrocytoma cells, colocalization of MLC1 and NaK-b1 was restricted to the perinuclear area and absent at the level of the plasma membrane (Fig. 3) . To validate this result with a biochemical approach, we set up the ouabain-affinity chromatography assay which takes advantage of the strong affinity of the alphasubunit of Na,K-ATPase for the cardiac glycoside ouabain and allows to isolate the Na,K-ATPase whole protein complex and its interactors (18, 32, 33) . Protein extracts derived from astrocytoma cell lines overexpressing WT and mutant MLC1 were purified on ouabain-affinity chromatography and, after elution, proteins associated with Na,K-ATPase were revealed by WB. In WT cell lines, MLC1 was specifically eluted along with NaK-b1 by K + and a high concentration of ouabain from the ouabain-affinity column, indicating specific association (Fig. 4) . Relatively to WT MLC1, a lower amount of S246R MLC1 was found associated with the Na,K-ATPase complex, while almost no MLC1 was eluted from the ouabain column when cellular extracts derived from S280L and C125R-expressing astrocytoma cells were analysed (Fig. 4) . Importantly, in the presence of all MLC1 mutations, including S246R, other components of the Na,K-ATPase macromolecular complex, such as the Kir4.1 potassium channel and the adaptor protein syntrophin, were not detectable or their binding was strongly reduced (Fig. 4) . Similar results were obtained with a His-protein co-purification assay that allows to isolate MLC1 interactors by exploiting the His-tag expressed at the NH 2 terminal of the MLC1 recombinant proteins (Supplementary Material, Fig. S1 ).
Since we demonstrated previously that hyposmotic treatment of primary rat astrocytes increased the association of MLC1 with the Na,K-ATPase complex (18), we examined MLC1/Na,K-ATPase interactions using ouabain-affinity chromatography in WT and mutated MLC1-overexpressing astrocytoma cells undergoing hyposmotic shock. These experiments showed that the association between MLC1 and the Na,K-ATPase complex was favoured by hyposmotic shock in WT-expressing cells. Conversely, no increase in the binding of MLC1 to the Na,K-ATPase complex was detected in any of the cell lines expressing mutant MLC1 (Supplementary Material, Fig. S2 ).
MLC1 mutations affect intracellular calcium influx in hyposmotic conditions
Although the above findings indicate that alterations in MLC1 association to the Na,K-ATPase complex could play a role in MLC pathogenesis through modification of the astrocyte response to osmotic imbalance, the precise function of MLC1 in this context remains to be elucidated. It has been shown that the decrease in extracellular osmolarity induces a transient and rapid swelling in astrocytes, followed by corrective processes of volume recovery named regulatory volume decrease (RVD) (34, 35) . The whole process occurs through sequential activation of different types of water and ion channels, exchangers and pumps (36, 37) , including Na,K-ATPase (38,39) and Kir4.1 (40) . A recent study demonstrated that astrocytes rapidly respond to hyposmosis by increasing intracellular calcium (Ca 2+ ) influx and that this influx is essential to activate RVD processes (41) . To understand the possible role of MLC1 in this regulatory loop, we investigated the swelling-induced changes in intracellular Ca 2+ concentration in WT and mutant MLC1-overexpressing astrocytoma cell lines using the FURA-2 video-imaging technique. In preliminary experiments, mock-infected astrocytoma cells loaded with the Ca 2+ indicator FURA-2 AM were challenged with a hyposmotic solution (60 mM NaCl) and Ca 2+ changes were analysed during a 10 min period. A fraction of astrocytoma cells reacted to hyposmotic shock with heterogeneous Ca 2+ transients that differed for lag time of onset, ranging from immediate to late-occurring profile of the transient (i.e. peak shaped, sustained or a combination of the two), and maximal amplitude of the Ca 2+ changes (Fig. 5A ). Hyposmotic shock never induced a Ca 2+ raise in the absence of extracellular Ca 2+ (Ca 2+ replaced by Mg 2+ and 0.5 mM EGTA added to the medium), confirming Ca 2+ influx as the main event causing the observed raise of intracellular Ca 2+ in these cells (Fig. 5B) .
When comparing the lag time of onset and the profile of the Ca 2+ transients, no differences were observed between control astrocytoma cells and cells infected with WT or mutated MLC1. However, we found that overexpression of WT MLC1 influenced the probability of occurrence (i.e. the fraction of responding cells) of the hyposmosis-induced Ca 2+ transient, the latter being 58% higher than in control cells, while overexpression of mutated MLC1 did not alter this parameter (Fig. 5C ). Moreover, Ca 2+ transients registered in cells overexpressing WT and S246R MLC1 were higher in amplitude compared with control cells, while the average amplitude of Ca 2+ transients in S280L and C125R cells was smaller than that in control cells (Fig. 5D ). Taken together, these data demonstrate that the MLC1 protein when expressed in the plasma membrane (MLC1 WT and S246R) regulates the response of astrocytes to hyposmosis by promoting Ca 2+ influx and that this process is inhibited by MLC1 mutations (S280L and C125R) reducing membrane-associated MLC1.
MLC1 mutations affect TRPV4-mediated calcium influx
Recent studies have shown that TRPV4 is the channel responsible for the increase of intracellular Ca 2+ and the consequent activation of RVD in astrocytes under hyposmotic stress (41, 42) . Preliminary WB experiments indicated that U251 cells express detectable levels of TRPV4 channel without quantitative differences between WT and mutated MLC1-expressing cells (Supplementary Material, Fig. S3 ). To understand whether the variations in intracellular Ca 2+ induced by hyposmotic shock in MLC overexpressing astrocytoma cells could be due to an effect on TRPV4 functionality, Figure 4 . Copurification of MLC1 and Na,K-ATPase by ouabain-affinity chromatography. Analysis of the eluted fractions from ouabain-affinity chromatography of U251 astrocytoma cell lines overexpressing WT and mutated MLC1. Fractions were analysed by SDS-PAGE and WB and probed with Abs against MLC1, Na,K-ATPase b1 (NaK-b1), Inward Rectifier K Channel 4.1 (Kir4.1) and syntrophin (Synt) (input). MLC1, Kir4.1, NaK-b1 and Synt were detected in the ouabain eluate (eluate) from the protein extract derived from WT cells. A lower amount of S246R MLC1 was found associated to the Na,K-ATPase complex relatively to WT protein, whereas almost no S280L and C125R MLC1-mutated proteins were found associated to the Na,K-ATPase complex. NaK-b1 was present in all the eluates. Kir4.1 was absent in the eluate derived from all MLC1 mutations. Syntrophin was found decreased in S246 and C125R and absent in S280L-derived eluates. Molecular weight markers are indicated on the left (kDa). astrocytoma cell lines were acutely treated with 4aPDD, a selective activator of the TRPV4 channel (43) . Application of a low concentration of 4aPDD (500 nM) induced a Ca 2+ rise in a fraction of cells, 13 + 2 and 3 + 1% in WT MLC1-and S280L-expressing cells, respectively. At this low concentration of the agonist, the amplitude of Ca 2+ transients did not differ between cells, being 1.0 + 0.2 and 0.7 + 0.15 R in control (Ctr) and WT cells, respectively, but the amount of responding cells was too low and the variability of the transients too large to allow a reliable comparison of the responses recorded in the different cell lines (data not shown). The application of a higher dose of 4aPDD (2 mM) induced slowly raising Ca 2+ transients which, similarly to those induced by hyposmotic shock, did not differ according to the lag time and profile (Fig. 6A) . Moreover, also in this case in the absence of Ca 2+ in the external solution, the Ca 2+ responses were not observed (Fig. 6B) influx (data not shown). Compared with mock-infected control cells, the probability of occurrence of the Ca 2+ transients increased by 54 and 63% in WT and S246R cells, respectively, but was unchanged or significantly reduced in S280L and C125R cells, respectively (Fig. 6C) . Lastly, also with a higher concentration of 4aPDD (2 mM), the average amplitude of the transients did not differ significantly among cell lines, being 1.7 + 0.1 and 1.4 + 0.2 R in control and S280L cells, respectively (Fig. 6D) . Thus, similarly to the hyposmosis-induced Ca 2+ influx, the TRPV4 agonist-induced Ca 2+ influx was also greatly potentiated when MLC1 was expressed in the plasma membrane. Taken together, these data depict a functional role of MLC1 in promoting a more efficient Ca 2+ influx through TRPV4 channels. In keeping with the selective involvement of these channels, both hyposmosis-and 4aPDD-induced Ca 2+ transients were completely abolished by ruthenium red (RR), a general blocker of TRPV ion channels (44) (Fig. 7 ).
MLC1 interacts with TRPV4: effect of MLC1 mutations
To investigate the possibility that MLC1 directly interacts with TRPV4 ion channels in astrocytes in preliminary experiments, we performed a pull-down assay using protein extracts derived from the cytosol and membrane fraction of rat astrocytes and the recombinant His-MLC1 protein bound to an His-affinity column. Figure 8 shows that TRPV4 was eluted from the MLC1-containing column along with the NaK-b1 used as a positive control in the cytosolic and membrane astrocyte fractions but not from a control column bound with bacterial non-specific proteins. We next verified the association of TRPV4 with the MLC1/Na,K-ATPase multiprotein complex in human astrocytoma cells and the possible effects of MLC1 mutations in isosmotic and hyposmotic conditions. To this purpose, we performed ouabain-affinity chromatography on WT and mutant MLC1-expressing human cells with or without hyposmotic treatment. We found that in WT-expressing cells, TRPV4 was associated to the MLC1/ Na,K-ATPase complex in control conditions and after hyposmotic shock (Fig. 9) . TRPV4 was also found in the Na,K-ATPase complex isolated from untreated S246R and C125R cells, albeit at lower levels compared with WT cells, but was almost undetectable after hyposmotic shock (Fig. 9) . In S280L-expressing cells, no TRPV4 was co-eluted with the ouabain complex, both in control conditions and after hyposmotic shock (Fig. 9) . Since in rat and mouse astrocytes, TRPV4 activates the cell response to hyposmosis in cooperation with the water channel aquaporin-4 (AQP-4) (41), we analysed whether AQP-4 is also part of the Na,K-ATPase/MLC1 complex. In WT-expressing cells, AQP-4 was detected in the Na,K-ATPase/MLC1 macromolecular complex only after hyposmosis treatment. In contrast, although some AQP-4 was found associated with the complex in untreated S246R and C125R cells, no AQP-4 protein was detected in any of the MLC1 mutant-expressing cells after hyposmotic shock (Fig. 9) .
Recently, a second gene linked to MLC disease has been identified that encodes for Hepacam/GlialCAM, a protein expressed in liver and brain whose function is still unknown (12) . It has been shown that this protein binds directly MLC1 (12, 45) . By WB analysis of ouabain eluates, we found that Hepacam/GlialCAM was present in the Na,K-ATPase/MLC1 macromolecular complex and that all MLC1 mutations analysed markedly reduced the association of Hepacam/GlialCAM to the protein complex both in control conditions and after hyposmotic shock (Fig. 9) .
DISCUSSION
With the aim of unravelling MLC1 protein function and the role of MLC1 gene mutations in MLC pathogenesis, we have generated human astrocytoma cell lines overexpressing WT and mutated MLC1. Using this in vitro system, we provide evidence that MLC1 functionally interacts with a macromolecular protein complex that includes Na,K-ATPase, Kir.4.1, AQP-4, TRPV4 and syntrophin. Most importantly, we show that through the functional interaction with the TRPV4 cation channel, MLC1 has a direct role in swelling-induced intracellular calcium influx in astrocytes and that pathological MLC1 mutations dysregulate this mechanism which is essential to activate the response of astrocytes to changes in the ionic environment. . RR inhibits the Ca 2+ transient induced by 4aPDD and hyposmotic shock. The TRPV channel inhibitor RR was used to characterize the nature of the channels involved in Ca 2+ influx triggered by hyposmotic shock. In these experiments, the potassium ionophore gramicidin (10 mg/ml), known for its ability to strengthen the hyposmosis-induced Ca 2+ influx, was used. When used in Fura-2 experiments, the totality of cells reacted to hyposmosis with a sudden and synchronous Ca 2+ raise, allowing an easier evaluation of the pharmacological sensitivity of hyposmosis-induced Ca 2+ raise. In this condition, RR (10 mM) completely abrogated both the 4aPDD-(A and B) and hyposmosis-induced (C and D) Ca 2+ signals, confirming the involvement of TRPV4 channels in the hyposmosis-induced Ca 2+ influx in astrocytoma cells. Figure 8 . Pull-down assay shows the interaction between MLC1 and TRPV4 in rat astrocytes. Cytosolic and membrane fractions from primary cultures of rat astrocytes (input) pulled-down by His-MLC1 and His-empty vector used as control bound to Ni-NTA agarose were eluted with 0.1 M glycine, pH 3. WB analysis using Abs against TRPV4 and Na,K-ATPase b1 subunit (NaK-b1) shows that TRPV4 interacts with His-MLC1, along with the NaK-b1 used as a positive control, in both cytoplasmic and membrane fractions. No bands are observed in the eluates derived from control column bound with bacterial unspecific proteins. Molecular weight markers are indicated on the left (kDa).
Characterization of the newly generated pathological model: effects of MLC1 mutations on MLC1 localization and molecular interactions
The generation of human astrocytoma cell lines overexpressing WT or mutated MLC1 has allowed, for the first time, to model MLC disease in a human background taking into account that MLC1 is mainly expressed in astrocytes and the current view that mutated MLC1 may cause alterations in astrocyte functions leading to brain damage. Altogether, the low level of endogenous MLC1 expression, the relatively easy and fast generation procedures, the possibility to obtain a considerable amount of material to performs biochemical assays and the correspondence with data obtained in rat primary astrocytes (see below) demonstrates that human astrocytoma cells carrying MLC1 mutations represent a useful model to investigate MLC1 functions and MLC pathogenesis. The detailed characterization of astrocytoma cells expressing WT MLC1 and three MLC1 mutations confirm previous observations in human HeLa cells that distinct pathological mutations differently influence MLC1 membrane expression (14) . Similarly to WT MLC1, the S246R mutated protein localizes in the plasma membrane, while S280L and C125R mutants are mainly confined to the ER. Similarly to what observed in rat astrocytes (18) , we show that in human astrocytoma cells expressing the WT protein MLC1 interacts with Na,K-ATPase and the associated multiprotein complex which includes Kir4.1 and syntrophin and is involved in the astrocyte response to osmotic imbalance (18 and references therein).
Our extended analysis of the MLC1/Na,K-ATPase-associated proteins reveals that in astrocytoma cells, TRPV4 and AQP-4 proteins also participate to the complex, and that hyposmotic treatment influences their association. The pathological relevance of these associations is highlighted by the finding that all the pathological missense mutations analysed influence the interaction of MLC1 with the Na,K-ATPase multiprotein complex. In particular, S280L and C125R mutations strongly affect MLC1 interaction with all the Na,K-ATPase-associated components analysed, whereas in cells overexpressing the S246R mutation MLC1 still interacts with Na,K-ATPase, TRPV4 and AQP-4, albeit at a lower level relatively to WT MLC1, but not with Kir4.1, in isosmotic conditions. However, S246R protein binding to Na,K-ATPase, TRPV4 and AQP-4 is markedly reduced after hyposmotic treatment. It is conceivable that the pathological effects of this mutation might be related to dynamic alterations in the molecular pathways in which these interactors are functionally involved in astrocytes. In light of these findings, the study of the pathological consequences of each single MLC1 mutation expressed in an astrocytic background emerges as a key step in the identification of specific, patient-tailored therapeutic strategies.
Among the Na,K-ATPase-associated proteins, we also found Hepacam/GlialCAM, the hepatic-glial adhesion molecule that was recently reported to interact with MLC1 (45) and whose gene mutations are associated with a fraction of MLC patients that do not carry mutations in the MLC1 gene (12) . Interestingly, the association of Hepacam/GlialCAM to the Na,K-ATPase complex was affected by MLC1 mutations similarly to TRPV4 and AQP-4 and further reduced by hyposmotic treatment of mutation-expressing astrocytoma cells, suggesting a possible involvement of Hepacam in astrocyte osmoregulatory processes. Because no difference in Hepacam localization was found in the brain of a patient carrying the MLC1 missense mutation S69L (45), we speculate that MLC1 mutations may affect the molecular relationships of Hepacam within the Na,K-ATPase-associated complex without altering its cellular localization. Alternatively, different mutations may affect MLC1 -Hepacam interaction in a different manner.
Recently, the junctional Zonula Occludens -1 (ZO-1) protein was found to coimmunoprecipitate with MLC1 (46). We have not investigated yet whether ZO-1 interacts with MLC1 or the Na,K-ATPase complex in astrocytoma cells. However, since the beta-1 subunit of the Na,K-ATPase, which binds MLC1 (18) , is involved in the formation and maintenance of adherens and tight junctional complexes (47 and references therein), it cannot be excluded that ZO-1 interacts with this multimolecular complex. Interestingly, also the cation channel TRPV4 has been reported to be present at cell -cell junctions (47) . Although the functional outcome of the molecular interactions described in this study is not yet fully understood, the finding that MLC1 mutations affect multiple components of the Na,K-ATPase complex protein underlines the pathological importance of these dynamic multiprotein associations.
MLC1 is a key player in the response of astrocytes to hyposmotic shock
Since pathological brain damages (1,2,7) and recent biochemical studies in cultured rat astrocytes (18) suggest possible defects in the control of water and ion homeostasis in MLC pathogenesis, in this study we have explored further the hypothesis that MLC1 is involved in the regulation of ion and fluid exchange in astrocytes. We demonstrate that in astrocytoma cells, MLC1 physically and functionally associates to a specific calcium-permeable cation channel, TRPV4. This channel belongs to the TRPV subfamily of the transient receptor potential (TRP) proteins, which includes six members (TRPV1 -6) homologous to the vanilloid receptor. Originally identified as a hyposmotically activated channel (48, 49) , TRPV4 is now recognized as a multimodal transducer that is activated by different stimuli, such as phorbol derivatives, moderate heat and mechanical stress (43, 50, 51) . TRPV4 is the cation channel responsible for swelling-induced cytosolic calcium increase and for the consequent RVD in response to hyposmosis in different type of cells (52) . Recent data obtained in rat astrocytes indicate that TRPV4 in cooperation with AQP-4 constitutes the main astroglial osmosensor (41, 42) regulating RVD also in hyposmotic astrocytes. Using FURA-2 analysis, we show that overexpression of MLC1 at the plasma membrane significantly enhances Ca 2+ influx induced by hyposmotic shock. Accordingly, in the presence of the specific TRPV4 agonist 4aPDD, we observed an increased probability of occurrence of intracellular calcium response in WT and S246R cells where MLC1 is present in the plasma membrane but not in S280L-and C125R-expressing cells, indicating that MLC1 interacts and functionally cooperates with the TRPV4 cation channel only when it is localized in the cell membrane. These findings suggest that defects in intracellular calcium transients in response to osmotic challenges may be involved in the pathogenetic mechanism underlying MLC disease. Unexpectedly, the average amplitude of 4aPDD-induced calcium signals did not differ in control and MLC1-expressing cells. This could not be explained by a saturating effect due to the high dose of agonist, since it was observed also at a lower concentration, but can be explained by considering this calcium signal in this cell type as an 'all or none' phenomenon. In this respect, it has to be recalled that TRPV4 is a multimodal transducer of a variety of stimuli and belongs to a multiprotein complex (see above), in which reciprocal regulations and cooperation among different players could ultimately determine a sort of 'threshold effect', compatible with our effect on the probability of occurrence rather than on the average amplitude of the event.
Although at present, we do not know whether MLC1 binds TRPV4 directly or by means of other intermediate proteins, the data obtained by pull-down and ouabain-chromatography clearly demonstrate that both in primary rat astrocytes and human astrocytoma cells, MLC1 and TRPV4 interact and participate to the same functional multiprotein complex. Interestingly, in the brain, the TRPV4 channel is strongly expressed in astrocyte end-feet surrounding blood vessels, ependyma and meninges (42), a localization that mimics that of MLC1 and suggests the possibility of their interaction in vivo. At the subcellular level, TRPV4 has been found in caveolae (52) where MLC1 and Na,K-ATPase are also expressed (31, 53, 54) . Therefore, it is conceivable that in astrocytes, MLC1-associated proteins can functionally cooperate in these compartments where the activity of mechanosensitive channels is strictly regulated during cell swelling (55) .
The increase in intracellular calcium in response to cell swelling is a key molecular event in the biochemical pathway responsible for initiation of volume recovery which enables cells to regain their former volume. RVD occurs in different cell types, including astrocytes (36, 41, (56) (57) (58) , and leads to a rapid efflux of organic and inorganic osmolytes followed by obligatory water extrusion (59, 60) . The presence of AQP-4 in the Na,K-ATPase/ TRPV4 protein complex found associated to WT MLC1 confirms that in astrocytoma cells these proteins are functionally linked to MLC1 and that MLC1 can contribute to RVD. Our preliminary experiments aimed at evaluating RVD in astrocytoma cells suggest that WT MLC1-expressing cells activate RVD more rapidly and efficiently than mutation-expressing cells (unpublished data), further supporting a key role for MLC1 in the osmoregulatory function and volume control processes in astrocytes.
During the preparation of this manuscript, a study by van der Knaap and co-authors (61) has been published showing that defects in chloride currents and hyposmosis-induced RVD are observed in patient-derived lymphoblasts and in rat astrocytes in which MLC1 expression is downregulated by siRNA. Because calcium influx in response to hyposmotic stimulus has been demonstrated to be the earliest event leading to activation of RVD and the associated chloride conductance, it is possible that the effects reported in that study (61) are linked to a defect in calcium channel activation (41, 62, 63) . Although this possibility deserves further investigations, our data corroborate this model by showing that astrocytoma cells overexpressing MLC1 in the plasma membrane activate calcium influx in response to hyposmosis and 4aPDD more efficiently than cells expressing mutations that hamper MLC1 localization in the plasma membrane and empty control cells. These findings indicate that defects in processes regulating calcium influx during hyposmosis are part of the pathogenetic mechanisms leading to MLC disease.
Conclusions
We have demonstrated that MLC1 mutations impair the functional interaction with the macromolecular protein complex that includes Na,K-ATPase, Kir4.1, AQP-4, TRPV4 and syntrophin. Although the molecular events underlying the cooperative actions of these proteins, such as factors regulating the relationship among individual proteins of the macromolecular complex, remain to be elucidated, the effects observed in astrocytoma cells expressing mutated MLC1 relatively to WT MLC1 support the idea that alterations in the astrocyte response to osmotic changes contribute to the brain abnormalities observed in MLC disease. The ability of cells to respond to anisotonic environment is a fundamental physiological function. Changes in the ionic composition of the extracellular space dynamically occur in physiological conditions, such as during neuronal electrical activity, brain development and aging (64) , and in pathological conditions such as trauma, ischemic insult, diabetes, inflammatory and infectious conditions (65) (66) (67) (68) (69) (70) . In the absence of astrocytic ionic homeostasis control, perturbations in the composition of the extracellular space can adversely affect normal brain function. It is worthwhile recalling that clinical conditions of MLC patients worsen after minor head trauma and common infections that often lead to epileptic seizures and coma (3 -5) . It is conceivable that MLC1 mutations induce astrocytic dysfunction in regulating extracellular ion homeostasis and cause the abnormal reactions to pathological insults observed in MLC patients.
In conclusion, results presented here open new perspectives for the elucidation of the molecular pathogenesis of MLC that is essential to develop a specific therapeutic approach to be offered to patients.
MATERIALS AND METHODS
Cloning of MLC1 mutations and generation of U251 astrocytoma cells overexpressing mutations C125R mutation was generated by site-direct mutagenesis as previously described (31) . To insert the His-tag at its NH 2 terminal, MLC1 carrying C125R mutations have been cloned in pcDNAV4-HIS as previously reported for WT MLC1 and S280L and S246R mutations (31) . All the cDNA-encoding MLC proteins along with the His-tag were subcloned in a retroviral bicistronic vector (pQCXIN, Clontech) by using PacI and EcoRI digestion and transfected in a packaging cell line (GP2 Hek293) to generate replication incompetent retroviral particles. Viral suspensions were used to infect U251 astrocytoma cell lines as previously described (71) . Cell lines infected with virus carrying the empty vector, used as control cells (CTR), or overexpressing recombinant MLC1 proteins (WT, S246R, S280L and C125R) were obtained by growing infected cells in G418 (gentamicin, Euroclone, Ltd, UK) containing selective medium.
Cell cultures and treatments
The glioblastoma U251-MG cell line was obtained from the American Type Culture Collection (Rockville, MD, USA) and grown in Dulbecco's modified Eagle's medium high glucose (DMEM, Euroclone, Ltd) supplemented with 10% FBS (Gibco BRL, Paisley, UK), 1% penicillin/streptomycin (Sigma Ltd, Irvine, UK) and 600 mg/ml G418 (Euroclone, Ltd) for selection at 378C in a 5% CO 2 /95% air atmosphere. Hyposmotic cell treatment was performed as previously described (18) for different time lengths. After stimulation, cells were washed in PBS, collected by scraping and centrifuged at 2.700g at 48C for 20 min. Cell pellets were solubilized as described below. Primary rat astrocytes were generated as previously described (72) .
Immunofluorescence and confocal microscopy analysis
Cells were grown subconfluent on polylysine-coated cover slips, fixed for 10 min with 4% paraformaldehyde and washed with PBS. After 1 h of incubation with blocking solution (5% BSA in PBS), cells were incubated for 1 h at RT with the following primary antibodies (Abs) diluted in PBS, 0.025% Triton X-100: affinity-purified anti-MLC1 pAb (1:50, Atlas AB, AlbaNova University Center, Stockholm, Sweden), anti-Na,K-ATPase b1 mAb (1:50, Millipore, Temecula, CA, USA) and anti-Calnexin mAb (1:70, BD Transduction Laboratories). A biotinilated secondary antibody (4.3 mg/ ml, Biotin-SP-AffiniPure goat anti-rabbit IgG H+L; Jackson Immunoresearch Laboratories, West Grove, PA, USA) followed by incubation with 2 mg/ml streptavidin-TRITC (Jackson, UK) or Alexa Fluor 488 goat anti-mouse IgG (1:300, Invitrogen, Milan, Italy) were used. To stain actin filaments, a NBD phallacidin high-affinity F-actin probe (1:30, Invitrogen) was used in combination with the primary anti-MLC1 pAb. Cover slips were washed, sealed in the Vectashield medium (Vector Lab, Burlingame, CA, USA) and analysed with a laser scanning confocal microscope (LSM 5 Pascal, Carl Zeiss, Jena, Germany).
Protein extract preparation and western blotting
Astrocytoma cell lines were lysed in buffer containing 1% Triton X-100, 0.5% sodium deoxycholate, 150 mM NaCl, 10 mM Hepes (pH 7.4) and protease inhibitor cocktail. Lysates were passed through a 26-gauge needle, incubated in ice for 20 min and centrifuged at 15.000g for 20 min at 48C. Protein samples were subjected to SDS-PAGE using gradient (4-12%) precasted gels (Invitrogen) (31), transferred to a nitrocellulose membrane and immunoblotted overnight at 48C with the following Abs: anti-MLC1 pAb (1:500, in-house generated), anti-Na,K-ATPase b1 mAb (1 mg/ml, Millipore), anti-Kir4.1 pAb (1:400, Alomone, Israel), anti-actin mAb (1:5000, Calbiochem-Oncogene Research Products, Cambridge, MA, USA), anti-syntrophin mAb (1:2000, MA-1-745, Affinity BioReagents, CO, USA), anti-AQP4 mAb (1:200, Santa Cruz Biotecnology, Inc., Santa Cruz, CA, USA), anti-TRPV4 pAb (1:200, Alomone) and antiHepacam pAb (1:1500, ProteinTech, Chicago, IL, USA) in PBS+3% BSA followed by extensive washings and then incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit Ab (1:10000; Thermo Scientific, MO, USA), for 1 h at RT. Immunoreactive bands were visualized using an enhanced chemiluminescence reagent (Pierce), according to the manufacturer's instructions and exposed on X-ray films.
Ouabain-affinity chromatography
The ouabain-affinity matrix was prepared according to a previously described procedure (18) . Cells derived from six confluent 175 cm 2 flask for each cell line untreated and treated with hyposmotic solution were incubated with ouabain column overnight. Eluition was carried out with 2 ml of elution buffer (10 mM ouabain, 25 mM imidazole, 150 mM NaCl and 1× protease inhibitor cocktail, pH 7.4) as previously described (18) . Samples obtained were analysed by SDS -PAGE and WB.
Pull-down assay with His-tagged MLC1 recombinant protein
A His-tagged recombinant human MLC1 protein was produced as previously described (16) . Briefly, the entire cDNA sequence of human MLC1 (accession number BC028425) was cloned into a six histidine-tagged prokaryotic inducible expression vector (pQE-30 UA, Qiagen, GmbH, Hilden, Germany). The recombinant protein was expressed in Escherichia coli cells and bound to Ni-NTA agarose resin (His-MLC1 resin) following the manufacturer's instructions (Qiagen) with minor modifications (16) . Protein extract derived from E. coli strain carrying the empty vector pQE-30 UA was used as control on Ni-Nta agarose resin (control resin). Cytosolic and membrane fractions from cultured rat astrocytes were extracted as previously described (31) . Supernatants obtained, diluted to a final concentration of 10 mM imidazole, were pre-cleared by incubation with the Ni-NTA agarose resin and then incubated with His-MLC1 resin or with control resin with gentle rocking for 2 h at 48C. Following exhaustive washes with 10-25 mM imidazole, 0.2% Triton X-100, 150 mM NaCl and 20 mM Tris-HCl, pH 7.4, protein-bound beads were eluted with 0.1 M glycine, pH 3. Aliquots (0.4 ml) of eluted proteins were precipitated with acetone (1:4 v/v) and analysed by SDS -PAGE and WB.
Intracellular Ca 21 measurement by FURA-2
Glass cover slips with strocytoma cells were placed in a recording chamber positioned on the stage of an inverted microscope (Axiovert 35, Zeiss, Germany), and connected to a perfusion system allowing the change of the bulk solution of the bath. In parallel, a local perfusion system (Rapid Solution Changer 100; Biologic) allowing the rapid switch between different solutions was also used. The control solution had the following composition: 122 mM NaCl, 3.3 mM KCl, 1.2 mM KH 2 PO 4 , 2.5 mM CaCl 2 , 0.4 mM MgSO 4 , 10 mM D-glucose and 25 mM HEPES/NaOH (RT, pH 7.4). Ca 2+ -free solutions were obtained by replacing the divalent ion by an equal amount of Mg 2+ and adding 0.5 mM EGTA. Hypotonic solution was obtained by removing 60 mM NaCl from normal solution. The TRPV4 agonist 4aPDD (Sigma-Aldrich Italia, Italy) was dissolved in DMSO to obtain a 10 mM stock solution, which was kept at 2208C and utilized to make freshly made final solutions every day. Intracellular Ca 2+ was measured by means of the video-imaging technique with the Ca 2+ sensitive probe Fura-2 (Invitrogen). Fura-2-AM loading was achieved by exposing cell cultures to a solution containing 2.5 mM Fura-2-AM for 50 min at RT, then the culture was washed and after 10 min it was used for recording. Fura-2-loaded cells were exposed to the excitation wavelengths 340 and 380 nm by means of a monochromator (Polychrome II, Photonics, Germany), and the emission light at 510 nm was collected by a digital camera (PCO, Sensicam, Germany) and recorded on the hard disk of a PC computer (Dell, USA). Recording and analysis of the data were made possible by the use of the Imaging Workbench software package (INDEC Systems, CA, USA). For further data processing and presentation, the Origin 7.5 software package (Microcal Software, NJ, USA) was utilized. Ca 2+ concentrations were expressed as ratio between the emission at 340 and 380 nm (R in the text). The amplitude of the Ca 2+ signals was calculated as maximal amplitude during the challenge minus baseline amplitude recorded before the challenge.
When testing the action of RR in Fura-2 Ca 2+ experiments, the potassium ionophore gramicidin (10 mg/ml, applied 5 min before recording), known for its capability to strengthen the hyposmosis-induced Ca 2+ influx, was used. In this condition, the totality of cells reacted to hyposmosis with a sudden and synchronous Ca 2+ raise, so allowing an easier evaluation of the pharmacological sensitivity of hyposmosis-induced Ca 2+ raise. Stock solutions were made by dissolving gramicidin in ethanol (20 mg/ml) and RR in water (10 mM), kept at 48C and used daily to make fresh solutions.
